<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Am J Otolaryngol</span><span class="iso-abbrev" title="iso-abbrev">Am J Otolaryngol</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">American Journal of Otolaryngology</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0196-0709</span><span class="issn-epub" tagx="issn" title="issn-epub">1532-818X</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Elsevier Inc.</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7301800">7301800</a></span><span class="publisher-id" title="publisher-id">S0196-0709(20)30312-4</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1016/j.amjoto.2020.102618">10.1016/j.amjoto.2020.102618</a></span><span class="publisher-id" title="publisher-id">102618</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Article</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">Mubarak Muhamed</span></span><span class="email" tagx="email" title="email">ent.khan@gmail.com</span><a href="#af0005">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parab</span><span class="given-names" tagx="given-names" title="given-names">Sapna Ramkrishna</span></span><span class="email" tagx="email" title="email">drsapnaparab@gmail.com</span><a href="#af0005">a</a><a href="#cr0005">â�Ž</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paranjape</span><span class="given-names" tagx="given-names" title="given-names">Mandar</span></span><a href="#af0010">b</a></span><span class="citation_author_institution" id="af0005">[a], </span><span class="citation_author_institution" id="af0010">[b], </span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">â�Ž</span>Corresponding author. <span class="email" tagx="email" title="email">drsapnaparab@gmail.com</span></div> </div><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-6-6</span></span><span class="pub-date-ppub" title="pub-date-ppub">ppub: <span>2020</span></span><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="volume" tagx="volume" title="volume">41</span><span class="issue" tagx="issue" title="issue">5</span><span class="fpage" tagx="fpage" title="fpage">102618</span><span class="lpage" tagx="lpage" title="lpage">102618</span><span class="history" title="history"><span class="received" title="received">received: 2020-6-5</span></span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">Elsevier Inc.</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="sec" title="sec"> <p>SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries.</p> </div> <div class="aims" title="sec"> <div class="title" tagx="title" title="title">
Aims</div> <p> </p><ul> <li><span class="label" tagx="label" title="label">1.</span><p id="p0005">To propose the use of 0.5% Povidone iodine gargles and nasal drops as prerequisite for office based nose and throat examination and procedures during COVID 19 pandemic.</p> </li> <li><span class="label" tagx="label" title="label">2.</span><p id="p0010">To assess tolerability of 0.5% PVP-I in patients and in healthcare workers.</p> </li> </ul> <p /> </div> <div class="materialsandmethods" title="sec"> <div class="title" tagx="title" title="title">
Materials and methods</div> <p>0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30â€¯s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted.</p> </div> <div class="results" title="sec"> <div class="title" tagx="title" title="title">
Results</div> <p>The patient and health care workers tolerated the 0.5%. No allergy was noted.</p> </div> <div class="conclusion" title="sec"> <div class="title" tagx="title" title="title">
Conclusion</div> <p>We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.</p> </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Povidone iodine</div> <div class="kwd" title="kwd">
SARS Cov</div> <div class="kwd" title="kwd">
SARS CoV 2</div> <div class="kwd" title="kwd">
MERS</div> <div class="kwd" title="kwd">
Prophylaxis</div> <div class="kwd" title="kwd">
Gargles</div> <div class="kwd" title="kwd">
Nasal spray</div> </div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1</span><div class="title" tagx="title" title="title">
Introduction</div> <p id="p0015">Iodine has been recognized as an effective bactericidal agent since the 1800s. Povidoneâ€‘iodine (iodine with the water-soluble polymer polyvinylpyrrolidone, PVP-I) was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. It was developed so as to find an alternative form of antimicrobial iodine complex that was less toxic than tincture of iodine. The onset of antimicrobial action of PVP-I starts when free iodine [<a href="#bb0005">1</a>] dissociates from the polymer complex. The free form of iodine rapidly penetrates microbes disrupting proteins and oxidising nucleic acid structures resulting ultimately in microbial death. PVP-I antibacterial activity is enhanced by dilution of the usually available 10% w/w cutaneous solution, from 1:2 dilution up to a 1:100 dilution (0Â·1%), with a reduction in activity occurring beyond 1:100 [<a href="#bb0010">2</a>,<a href="#bb0015">3</a>]. PVP-I has higher virucidal activity than other commonly used antiseptic agents including chlorhexidine [<a href="#bb0020">4</a>] and benzalkonium chloride. PVP-I has been shown to be active in-vitro against the coronaviruses that have caused epidemics of SARS (severe acute respiratory syndrome epidemic of 2002â€"2003) and MERS (Middle East respiratory syndrome epidemic of 2012â€"2013) [<a href="#bb0025">5</a>,<a href="#bb0030">6</a>].</p> <p id="p0020">SARS-CoV-2 causing the COVID 19 Pandemic is highly homologous with SARS-CoV [<a href="#bb0035">7</a>]. In-vitro study by Eggers et al. [<a href="#bb0025">5</a>] on the virucidal activity of PVP-I against MERS-CoV showed that the lowest concentration of PVP-I to be effective was 1% when used for 30â€¯s under â€œdirtyâ€� conditions, leading to a reduction of viral activity of â‰¥99.99%; but not effective at 0Â·1% [<a href="#bb0025">5</a>]. In subsequent in-vitro work by Eggers et al. [<a href="#bb0030">6</a>], the lowest concentration tested and effective against coronaviruses, was 0Â·23%. Kariwa et al. showed that in vitro treatment of SARS-CoV with various preparations of PVP-I for 2â€¯min reduced the viral activity to untraceable levels [<a href="#bb0040">8</a>]. The lowest concentration throat spray (Isodine Nodo FreshÂ®) of 0.23% was used in Japan. In many orthopaedic and ophthalmic surgeries PVP-I is used as preoperative agent for Decolonization of Nasal <i>Staphylococcus aureus</i> and many infections [<a href="#bb0045">[9]</a>, <a href="#bb0050">[10]</a>, <a href="#bb0055">[11]</a>]. In many ophthalmic surgeries, different dilutions of PVP-I are used for avoiding contamination and it is well tolerated [<a href="#bb0060">12</a>].</p> <p id="p0025">The oropharynx and nasopharynx are the target sites of novel coronavirus with the result that saliva contains a high viral load of COVID 19 with up to 1.2â€¯Ã—â€¯10<sup>8</sup> infective copies/per ml [<a href="#bb0065">13</a>]. As an otorhinolaryngologist is closely working in this area, there is a significant risk of exposure during routine office based examinations of Ear, Nose and Throat and many endoscopy procedures. Even a few microliters of saliva contamination of surfaces or instruments may carry many thousands of infectious viral particles. Though asymptomatic, the viral shedding initial phase of COVID 19 is highly infectious [<a href="#bb0070">14</a>]. At present there are no universal guidelines either for preoperative testing or for treatment of for COVID 19, and individual hospitals are creating their own protocols of treatment and prophylaxis. Povidone Iodine (PVP-I) has better antiviral activity than other antiseptics such as chlorhexidine [<a href="#bb0020">4</a>] and has already been proven to be an effective virucidal in vitro against similar coronaviruses (SARS â€"CoV and MERS-Cov) [<a href="#bb0025">5</a>,<a href="#bb0030">6</a>,<a href="#bb0040">8</a>] although it has not been tested directly with COVID 19. Hence, we propose the use of 0.5% PVP-I as gargles and nasal drops as a prerequisite for patients attending ENT Out-Patient department and health care workers attending these patients.</p> </div> <div class="methodsandmaterials" title="sec"><span class="label" tagx="label" title="label">2</span><div class="title" tagx="title" title="title">
Methods and materials</div> <p id="p0030">All health care workers and patients attending out-patient department for consultations and for ENT endoscopies in the month of May were included in the study. This included patients with no symptoms of COVID-19 having procedures in or around the mouth and nose or procedures that transit those areas and the healthcare professionals carrying out those procedures due to the high incidence of asymptomatic infection.</p> <div class="exclusioncriteria" title="sec"><span class="label" tagx="label" title="label">2.1</span><div class="title" tagx="title" title="title">
Exclusion criteria</div> <p id="p0035">Patients with history of allergy to PVP-I, all forms of thyroid disease or on radioactive iodine treatment, lithium therapy, known pregnancy, renal failure and dermatitis were excluded from the study. The protocol can be used in children as a single application for Nose, Throat examination after excluding allergy.</p> <p id="p0040"><u>The detailed protocol adopted is as follows</u>:</p> <p id="p0045">In the hospital setting, we propose application of 0Â·5% PVP-I solution (0Â·55â€¯mg/mL available iodine) as gargles onto the oral, oropharyngeal mucosa and as nasal drops onto nasal and nasopharyngeal mucosa of patients with suspected/confirmed COVID-19 and the healthcare workers in close contact with such patients and all routine patients seeking ENT consultation whose COVID 19 status is unknown. Additionally, the application of 0.5% PVP-I can be used for oral surgery, ENT examination and treatment, <i>endo</i>-tracheal intubation, endoscopy and bronchoscopy as a preoperative preparation.</p> <p id="p0050"><u>Preparation of 0.5% solution of PVP-I from commercially available solution</u>: </p><ul> <li><span class="label" tagx="label" title="label">A.</span><p id="p0055">Povidone Iodine IP 10% v/w in purified water IP q.s.: Use 1â€¯ml of PVP-I in 20â€¯ml of sterile water/purified water.</p> </li> <li><span class="label" tagx="label" title="label">B.</span><p id="p0060">Povidone Iodine IP 5% v/w in purified water IP q.s.: Use 1â€¯ml of PVP-I in 10â€¯ml of sterile water/purified water.</p> </li> <li><span class="label" tagx="label" title="label">C.</span><p id="p0065">Povidone Iodine IP 7.5% v/w in purified water IP q.s.: Use 1â€¯ml of PVP-I in 15â€¯ml of sterile water/purified water.</p> </li> <li><span class="label" tagx="label" title="label">D.</span><p id="p0070">Povidone Iodine IP 2.5% v/w in purified water IP q.s.: Use 1â€¯ml of PVP-I in 5â€¯ml of sterile water/purified water.</p> </li> </ul> <p /> <p id="p0075"><u>Method of application</u>: </p><ul> <li><span class="label" tagx="label" title="label">1.</span><p id="p0080"><u>For ENT Examination and for endoscopies</u></p> <p id="p0085">Step 1 â€" for all patients/healthcare professionals: The 0Â·5% PVP-I solution is administered in a dose of 4â€"5 drops into each nostril 10â€¯min prior to examination. For endoscopic procedure, nasal pack with PVP is used and prior nasal douching 2 times prior day.</p> <p id="p0090">Step 2 â€" conscious patients and healthcare professionals: 10â€¯ml of the 0Â·5% PVP-I solution is then introduced into the oral cavity and used as a mouthwash. Care is taken to ensure the solution is distributed throughout the oral cavity for 30â€¯s and then gently gargled or held at the back of the throat for another 30â€¯s before spitting out.</p> </li> <li><span class="label" tagx="label" title="label">2.</span><p id="p0095"><u>For hospitalised patients</u>: Patients hospitalised for confirmed/suspected COVID 19 and the involved healthcare workers: Steps 1 &amp;amp; 2 should be undertaken every 6â€¯h for patients and up to four times per day for healthcare workers (maximal frequency two hourly). For healthcare workers, it is advised that steps 1 &amp;amp; 2 are performed prior to contact with the patients and if repeated contact is occurring, steps 1 and 2 are at a frequency up to 4 times in a day or repeated every 2â€"3â€¯h.</p> </li> <li><span class="label" tagx="label" title="label">3.</span><p id="p0100"><u>Endoscopy and bronchoscopy and any other action to be carried out close to or in the mouth or nose</u>: The patient should undergo steps 1 &amp;amp; 2 prior to examination or treatment. Healthcare workers conducting the procedure or in close proximity should perform steps 1 &amp;amp; 2 prior to contact with the patient and if multiple patients are being seen, repeat every 2â€"3â€¯h, up to 4 times a day. Dosages are the same as above, but are single exposures for patients.</p> </li> </ul> <p /> </div> </div> <div class="results" title="sec"><span class="label" tagx="label" title="label">3</span><div class="title" tagx="title" title="title">
Results</div> <p id="p0105">All the patients and the health care workers were enquired for any irritation or discomfort following nasal douching and gargling. A total of 315 patients were evaluated and underwent nose and throat endoscopies. All except 7 were comfortable with PVP-I gargles and nasal drops (<a href="#t0005">Table 1</a> ). 17 health care workers used the 0.5% PVP-I nasal drops and gargles. No allergy was reported by any of the patients and health care workers. <div class="table-wrap_UNKNOWN" position="float" id="t0005"><span class="label" tagx="label" title="label">Table 1</span> </div></p><p>Procedure wise age -gender distribution of the study population.</p>  <div tag="alt-text">
Table 1</div> <table frame="hsides" rules="groups"> <thead> <tr> <th rowspan="2">Age in years</th> <th colspan="2">Nasal endoscopy <hr /> </th> <th colspan="2">Throat endoscopy <hr /> </th> <th rowspan="2">Total</th> </tr> <tr> <th>Male</th> <th>Female</th> <th>Male</th> <th>Female</th> </tr> </thead> <tbody> <tr> <td>18 to 30</td> <td align="char">32</td> <td align="char">27</td> <td align="char">26</td> <td align="char">15</td> <td align="char">100</td> </tr> <tr> <td>31 to 45</td> <td align="char">26</td> <td align="char">39</td> <td align="char">17</td> <td align="char">20</td> <td align="char">102</td> </tr> <tr> <td>&amp;gt;45</td> <td align="char">39</td> <td align="char">25</td> <td align="char">25</td> <td align="char">24</td> <td align="char">113</td> </tr> <tr> <td>Total</td> <td align="char">97</td> <td align="char">91</td> <td align="char">68</td> <td align="char">59</td> <td align="char">315</td> </tr> </tbody> </table>  <p /> </div> <div class="discussion" title="sec"><span class="label" tagx="label" title="label">4</span><div class="title" tagx="title" title="title">
Discussion</div> <p id="p0110">PVP-I is being extensively used worldwide as a handwashing agent (usually a 7Â·5% solution containing foaming agents), for pre-procedural skin antisepsis [<a href="#bb0075">15</a>] (usually simply as a 10% solution), in ophthalmic surgery [<a href="#bb0050">10</a>,<a href="#bb0060">12</a>] (often diluted to 5%) and in oral surgery as 10%. The PVP-I is commercially available in the Far East as a 1% w/v mouthwash for use every 2â€"4â€¯h [<a href="#bb0080">16</a>]. It is assumed that using a concentration twice as strong as that found to be virucidal in vitro (0Â·5% versus 0Â·23% [<a href="#bb0025">5</a>,<a href="#bb0040">8</a>]) will be effective to allow for dilution due to saliva as the exact effective concentration of PVP-I in the presence of mucins and saliva is not known.</p> <p id="p0115">The intranasal topical application of 0.08% solution of iodine for the treatment of recalcitrant chronic rhinosinusitis has been described by the St. Paul's Sinus Centre team in Vancouver [<a href="#bb0085">17</a>,<a href="#bb0090">18</a>]. This application did not cause any significant effect on thyroid function, mucociliary clearance or olfaction. PVP-I use in the nasal cavity to reduce infection or spread is rational for COVID-19 after two recent trials have demonstrated higher viral load there when compared with the oral cavity [<a href="#bb0025">5</a>,<a href="#bb0030">6</a>,<a href="#bb0040">8</a>].</p> <p id="p0120">PVP-I gargles are very well tolerated as compared to other antiseptic agents gargles [<a href="#bb0020">4</a>]. It has been demonstrated in clinically successfully trials that nasal administration and mouthwash reduced pharyngeal bacterial colonization and subsequent reduction in the incidence of nosocomial pneumonia [<a href="#bb0095">19</a>]. Povidone-Iodine-Based Solutions are used as preoperative asepsis preparation in many planned orthopaedic and ophthalmic surgeries for Decolonization of Nasal microbes [<a href="#bb0045">9</a>,<a href="#bb0050">10</a>].</p> <p id="p0125">Considering the antiviral actions of Povidone Iodine at various sites including the extensive use by ophthalmologists for a delicate sensitive special sense organ concerned with vision [<a href="#bb0050">[10]</a>, <a href="#bb0055">[11]</a>, <a href="#bb0060">[12]</a>], there is absolutely no harm in repurposing 0.5% PVP-I to another two special senses' organ for extrapolating its probable antiviral action against SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles. And pre-procedure testing for COVID 19 infection, may not be feasible in all patients attending the clinic. Moreover, a false negative test creates a pseudo feeling of security amongst the health care workers. The evidence presented suggests that application of povidone iodine to the nasal and oral mucosa, oropharynx and nasopharynx of patients with COVID-19 may significantly reduce the viral load in these key anatomical areas. This will definitely help to reduce the risk of transmission to health care workers. It also allows a time period to perform procedures at reduced risk. Further reduction of risk of transmission may be achieved by similar application of PVP-I to the HCW providing the care as a form of prophylaxis. We therefore propose that for the duration of the current COVID-19 pandemic. At low concentrations, staining of teeth is minimal and reversible.</p> <p id="p0130">We do accept that direct testing and demonstration of the virucidal activity of PVP I against SARS-CoV-2 has not been yet documented. However, the experience gained from the previous studies by Eggers et al. [<a href="#bb0025">5</a>,<a href="#bb0030">6</a>] showing in vitro virucidal action of PVP-I in SARS COV and MERS [<a href="#bb0040">8</a>], we propose to use it for reduction of SAR-CoV-2 viral load in the oral cavity to prevent COVID 19 transmission in the suggested manner. We propose this protocol for disinfection of the oral, oropharyngeal, nasopharyngeal and nasal cavities, similar to the recommended practice of hand sanitisation for transmission reduction. It will potentially prevent the infected patients from passing on the virus and at a portal of virus entry for HCW (potentially protecting them from being infected via the nose/mouth). It is accepted that aerosolised secretions from the lower respiratory tract almost certainly have a part to play in disease transmission and therefore that this proposal forms only part of the strategy to reduce transmission, in addition to the use of personal protective equipment by the health care workers.</p> <p id="p0135">We propose that protocolled nasal drops/douching and oropharyngeal wash of PVP-I should be used in current COVID 19 pandemic to limit the spread of SARS â€" COV-2 from patients to healthcare workers and potentially vice versa. We propose that no office based ENT examination, office based endoscopic procedures, planned surgical procedures and intubation should be carried out without disinfection by PVP-I. Although, we have not estimated the effective reduction in the viral titres of coronavirus 2, but we theoretically presume depending on past studies that the reduction in the titres is possible and can last at least for 20â€¯min in vivo [<a href="#bb0025">5</a>,<a href="#bb0030">6</a>,<a href="#bb0040">8</a>]. The reduction in the titres as well as the length of time for which antisepsis remains has to be researched by various randomised controlled studies. A risk free time of 20â€¯min following the use of PVP-I should be sufficient for examination and short procedures. The question of total iodine exposure seems well within previously recorded safe limits in those without contraindications to its use (history of allergy [<a href="#bb0100">20</a>] to PVP, thyroid diseases [<a href="#bb0105">21</a>], dermatitis [<a href="#bb0110">22</a>] etc.) as only PVP-I is used just before examination. Urgent consideration should be given to the application of PVP-I to patients and HCWs as described above.</p> <p id="p0140">The points in favour of the study: </p><ul> <li><span class="label" tagx="label" title="label">1.</span><p id="p0145">Previous studies proving the effectiveness of PVP-I against MERS and SARS CoV</p> </li> <li><span class="label" tagx="label" title="label">2.</span><p id="p0150">The structural similarity of SARS CoV, SARS CoV 2 and MERS</p> </li> <li><span class="label" tagx="label" title="label">3.</span><p id="p0155">0.5% PVP-I is easy to prepare and is inexpensive</p> </li> <li><span class="label" tagx="label" title="label">4.</span><p id="p0160">PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally</p> </li> <li><span class="label" tagx="label" title="label">5.</span><p id="p0165">It is easy to dispense to patients and to health care workers</p> </li> <li><span class="label" tagx="label" title="label">6.</span><p id="p0170">No reported allergies</p> </li> <li><span class="label" tagx="label" title="label">7.</span><p id="p0175">Though not proved, it probably reduces the viral titres of SARS CoV 2</p> </li> </ul> <p /> <p id="p0180">Limitations: Quantitative studies estimating the total reduction of the viral titres of SARS CoV 2 and the time duration for which the antiviral activity lasts.</p> </div> <div class="conclusion" title="sec"><span class="label" tagx="label" title="label">5</span><div class="title" tagx="title" title="title">
Conclusion</div> <p id="p0185">With the considerable past evidence of benefit of the use of PVP-I antiseptic against SARS Cov and MERS in maintenance of oral health prevention and treatment of oropharyngeal infections, we propose the immediate use of PVP-I in healthcare workers and their patients as described to minimise the risk of spread of the disease as an addition to currently recommended PPE used during management of COVID-19 patients. Amidst the deadly menace, we are extrapolating the in vitro efficacy of very economical PVP-I to apply it for in vivo use as there is no harm in considering the potential use of PVP-I in reducing Viral load in oropharyngeal and nasal cavities.</p> </div> <div class="funding" title="sec"> <div class="title" tagx="title" title="title">
Funding</div> <p id="p0190">This study was not financially supported from external sources.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Declaration of competing interest</div> <p id="p0195">None.</p> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="bb0005" /><span class="label" tagx="label" title="label">1</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wada</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nojima</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ogawa</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Relationship between virucidal efficacy and free iodine concentration of povidone-iodine in buffer solution</span><span class="source" tagx="source" title="source">Biocontrol Sci</span><span class="volume" tagx="volume" title="volume">21</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">21</span><span class="lpage" tagx="lpage" title="lpage">27</span><span class="pub-id"><a href="https://dx.doi.org/10.4265/bio.21.21">10.4265/bio.21.21</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27009506">27009506</a></span></span></li> <li tag="ref"><a name="bb0010" /><span class="label" tagx="label" title="label">2</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Berkelman</span><span class="given-names" tagx="given-names" title="given-names">R.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Holland</span><span class="given-names" tagx="given-names" title="given-names">B.W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anderson</span><span class="given-names" tagx="given-names" title="given-names">R.L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Increased bactericidal activity of dilute preparations of povidone-iodine solutions</span><span class="source" tagx="source" title="source">J Clin Microbiol</span><span class="volume" tagx="volume" title="volume">15</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">1982</span><span class="fpage" tagx="fpage" title="fpage">635</span><span class="lpage" tagx="lpage" title="lpage">639</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7040461">7040461</a></span></span></li> <li tag="ref"><a name="bb0015" /><span class="label" tagx="label" title="label">3</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rahn</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Review presentation on povidone-iodine antisepsis in the oral cavity</span><span class="source" tagx="source" title="source">Postgrad Med J</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">Suppl. 3</span><span class="year" tagx="year" title="year">1993</span><span class="fpage" tagx="fpage" title="fpage">S4</span><span class="lpage" tagx="lpage" title="lpage">S9</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8290456">8290456</a></span></span></li> <li tag="ref"><a name="bb0020" /><span class="label" tagx="label" title="label">4</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">da Silveira Teixeira</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Figueiredo</span><span class="given-names" tagx="given-names" title="given-names">M.A.Z.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cherubini</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Oliveira</span><span class="given-names" tagx="given-names" title="given-names">S.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salum</span><span class="given-names" tagx="given-names" title="given-names">F.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The topical effect of chlorhexidine and povidone-iodine in the repair of oral wounds. A review</span><span class="source" tagx="source" title="source">Stomatologija</span><span class="volume" tagx="volume" title="volume">21</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">35</span><span class="lpage" tagx="lpage" title="lpage">41</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32108654">32108654</a></span></span></li> <li tag="ref"><a name="bb0025" /><span class="label" tagx="label" title="label">5</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eggers</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koburger-Janssen</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eickmann</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zorn</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens</span><span class="source" tagx="source" title="source">Infect Dis Ther</span><span class="volume" tagx="volume" title="volume">7</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">249</span><span class="lpage" tagx="lpage" title="lpage">259</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40121-018-0200-7">10.1007/s40121-018-0200-7</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29633177">29633177</a></span></span></li> <li tag="ref"><a name="bb0030" /><span class="label" tagx="label" title="label">6</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eggers</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eickmann</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zorn</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rapid and effective virucidal activity of povidone-iodine products against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA)</span><span class="source" tagx="source" title="source">Infect Dis Ther</span><span class="volume" tagx="volume" title="volume">4</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2015</span><span class="fpage" tagx="fpage" title="fpage">491</span><span class="lpage" tagx="lpage" title="lpage">501</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40121-015-0091-9">10.1007/s40121-015-0091-9</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26416214">26416214</a></span></span></li> <li tag="ref"><a name="bb0035" /><span class="label" tagx="label" title="label">7</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zheng</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS-CoV-2: an emerging coronavirus that causes a global threat</span><span class="source" tagx="source" title="source">Int J Biol Sci</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1678</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32226285">32226285</a></span></span></li> <li tag="ref"><a name="bb0040" /><span class="label" tagx="label" title="label">8</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kariwa</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fujii</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Takashima</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents</span><span class="source" tagx="source" title="source">Dermatology (Basel, Switzerland)</span><span class="volume" tagx="volume" title="volume">212</span><span class="year" tagx="year" title="year">2006</span><span class="fpage" tagx="fpage" title="fpage">119</span><span class="lpage" tagx="lpage" title="lpage">123</span><span class="pub-id"><a href="https://dx.doi.org/10.1159/000089211">10.1159/000089211</a></span><span class="comment">Suppl</span></span></li> <li tag="ref"><a name="bb0045" /><span class="label" tagx="label" title="label">9</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rezapoor</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nicholson</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tabatabaee</span><span class="given-names" tagx="given-names" title="given-names">R.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">A.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maltenfort</span><span class="given-names" tagx="given-names" title="given-names">M.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parvizi</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Povidone-iodine-based solutions for decolonization of nasal <i>Staphylococcus aureus</i>: a randomized, prospective, placebo-controlled study</span><span class="source" tagx="source" title="source">J Arthroplasty</span><span class="volume" tagx="volume" title="volume">32</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">2815</span><span class="lpage" tagx="lpage" title="lpage">2819</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.arth.2017.04.039">10.1016/j.arth.2017.04.039</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28578841">28578841</a></span></span></li> <li tag="ref"><a name="bb0050" /><span class="label" tagx="label" title="label">10</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koerner</span><span class="given-names" tagx="given-names" title="given-names">J.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">George</span><span class="given-names" tagx="given-names" title="given-names">M.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meyer</span><span class="given-names" tagx="given-names" title="given-names">D.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rosco</span><span class="given-names" tagx="given-names" title="given-names">M.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Habib</span><span class="given-names" tagx="given-names" title="given-names">M.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Povidone-iodine concentration and dosing in cataract surgery</span><span class="source" tagx="source" title="source">Surv Ophthalmol</span><span class="volume" tagx="volume" title="volume">63</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">862</span><span class="lpage" tagx="lpage" title="lpage">868</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.survophthal.2018.05.002">10.1016/j.survophthal.2018.05.002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29778494">29778494</a></span></span></li> <li tag="ref"><a name="bb0055" /><span class="label" tagx="label" title="label">11</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GonzÃ¡lez-MartÃ­n-Moro</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zarallo-Gallardo</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Iodine povidone. A new paradigm in the treatment of adenoviral conjunctivitis?</span><span class="comment">Povidona yodada. Â¿Un nuevo paradigma en el tratamiento de la conjuntivitis adenovÃ­rica?</span><span class="source" tagx="source" title="source">Arch Soc Esp Oftalmol</span><span class="volume" tagx="volume" title="volume">94</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">521</span><span class="lpage" tagx="lpage" title="lpage">522</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.oftal.2019.07.013">10.1016/j.oftal.2019.07.013</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31500885">31500885</a></span></span></li> <li tag="ref"><a name="bb0060" /><span class="label" tagx="label" title="label">12</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silas</span><span class="given-names" tagx="given-names" title="given-names">M.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schroeder</span><span class="given-names" tagx="given-names" title="given-names">R.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thomson</span><span class="given-names" tagx="given-names" title="given-names">R.B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Myers</span><span class="given-names" tagx="given-names" title="given-names">W.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0</span><span class="source" tagx="source" title="source">J Cataract Refract Surg</span><span class="volume" tagx="volume" title="volume">43</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">400</span><span class="lpage" tagx="lpage" title="lpage">404</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jcrs.2017.01.007">10.1016/j.jcrs.2017.01.007</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28410725">28410725</a></span></span></li> <li tag="ref"><a name="bb0065" /><span class="label" tagx="label" title="label">13</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">To</span><span class="given-names" tagx="given-names" title="given-names">K.K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tsang</span><span class="given-names" tagx="given-names" title="given-names">O.T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yip</span><span class="given-names" tagx="given-names" title="given-names">C.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chan</span><span class="given-names" tagx="given-names" title="given-names">K.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">T.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chan</span><span class="given-names" tagx="given-names" title="given-names">J.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Consistent detection of 2019 novel coronavirus in saliva</span><span class="source" tagx="source" title="source">Clin Infect Dis</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">12</span><span class="comment">Feb</span></span></li> <li tag="ref"><a name="bb0070" /><span class="label" tagx="label" title="label">14</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">He</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lau</span><span class="given-names" tagx="given-names" title="given-names">E.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deng</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hao</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Temporal dynamics in viral shedding and transmissibility of COVID-19</span><span class="source" tagx="source" title="source">Nat Med</span><span class="volume" tagx="volume" title="volume">26</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">672</span><span class="lpage" tagx="lpage" title="lpage">675</span><span class="comment">May</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32296168">32296168</a></span></span></li> <li tag="ref"><a name="bb0075" /><span class="label" tagx="label" title="label">15</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Urias</span><span class="given-names" tagx="given-names" title="given-names">D.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Varghese</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Simunich</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Morrissey</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dumire</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Preoperative decolonization to reduce infections in urgent lower extremity repairs</span><span class="source" tagx="source" title="source">Eur J Trauma Emerg Surg</span><span class="volume" tagx="volume" title="volume">44</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">787</span><span class="lpage" tagx="lpage" title="lpage">793</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00068-017-0896-1">10.1007/s00068-017-0896-1</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29306970">29306970</a></span></span></li> <li tag="ref"><a name="bb0080" /><span class="label" tagx="label" title="label">16</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Domingo</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Farrales</span><span class="given-names" tagx="given-names" title="given-names">M.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Loya</span><span class="given-names" tagx="given-names" title="given-names">R.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pura</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Uy</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene</span><span class="source" tagx="source" title="source">J Philipp Dent Assoc</span><span class="volume" tagx="volume" title="volume">48</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">1996</span><span class="fpage" tagx="fpage" title="fpage">31</span><span class="lpage" tagx="lpage" title="lpage">38</span></span></li> <li tag="ref"><a name="bb0085" /><span class="label" tagx="label" title="label">17</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Panchmatia</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Payandeh</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Salman</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study</span><span class="source" tagx="source" title="source">Eur Arch Otorhinolaryngol</span><span class="year" tagx="year" title="year">2019</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s00405-019-05628-w">10.1007/s00405-019-05628-w</a></span><span class="comment">Published Online First</span></span></li> <li tag="ref"><a name="bb0090" /><span class="label" tagx="label" title="label">18</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mullings</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Panchmatia</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Samoy</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Topical povidone-iodine as an adjunctive treatment for recalcitrant chronic rhinosinusitis</span><span class="source" tagx="source" title="source">European Journal of Rhinology and Allergy</span><span class="year" tagx="year" title="year">2019</span><span class="pub-id"><a href="https://dx.doi.org/10.5152/ejra.2019.166">10.5152/ejra.2019.166</a></span><span class="comment">Published Online First</span></span></li> <li tag="ref"><a name="bb0095" /><span class="label" tagx="label" title="label">19</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kawana</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kudo</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A trial of povidone-iodine (PVP-I) nasal inhalation and gargling to remove potentially pathogenic bacteria colonized in the pharynx</span><span class="source" tagx="source" title="source">Kansenshogaku zasshi The Journal of the Japanese Association for Infectious Diseases</span><span class="volume" tagx="volume" title="volume">73</span><span class="year" tagx="year" title="year">1999</span><span class="fpage" tagx="fpage" title="fpage">429</span><span class="lpage" tagx="lpage" title="lpage">436</span><span class="pub-id"><a href="https://dx.doi.org/10.11150/kansenshogakuzasshi1970.73.429">10.11150/kansenshogakuzasshi1970.73.429</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386022">10386022</a></span></span></li> <li tag="ref"><a name="bb0100" /><span class="label" tagx="label" title="label">20</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kunze</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kaiser</span><span class="given-names" tagx="given-names" title="given-names">H.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Petres</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Relevanz einer Jodallergie bei handelsÃ¼blichen Polyvidon-Jod-Zubereitungen</span><span class="trans-source" tagx="trans-source" title="trans-source">Relevance of an iodine allergy to commercial polyvidone-iodine preparations</span><span class="source" tagx="source" title="source">Z Hautkr</span><span class="volume" tagx="volume" title="volume">58</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">1983</span><span class="fpage" tagx="fpage" title="fpage">255</span><span class="lpage" tagx="lpage" title="lpage">261</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6845795">6845795</a></span></span></li> <li tag="ref"><a name="bb0105" /><span class="label" tagx="label" title="label">21</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ader</span><span class="given-names" tagx="given-names" title="given-names">A.W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paul</span><span class="given-names" tagx="given-names" title="given-names">T.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reinhardt</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function</span><span class="source" tagx="source" title="source">J Clin Endocrinol Metabol</span><span class="year" tagx="year" title="year">1988</span><span class="pub-id"><a href="https://dx.doi.org/10.1210/jcem-66-3-632">10.1210/jcem-66-3-632</a></span><span class="comment">Published Online First</span></span></li> <li tag="ref"><a name="bb0110" /><span class="label" tagx="label" title="label">22</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lachapelle</span><span class="given-names" tagx="given-names" title="given-names">J.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Allergic contact dermatitis from povidone-iodine: a re-evaluation study</span><span class="source" tagx="source" title="source">Contact Dermatitis</span><span class="year" tagx="year" title="year">2005</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.0105-1873.2005.00479.x">10.1111/j.0105-1873.2005.00479.x</a></span><span class="comment">Published Online First</span></span></li> </ul> </div> </div>  </body></html>